Go Pro
→ Bezos… DOOMED (From Paradigm Press) (Ad)tc pixel Free CLVR Stock Alerts

Clever Leaves (CLVR) Competitors

Clever Leaves logo
$0.0002 0.00 (0.00%)
As of 09/2/2026
Compare

CLVR vs. SXTPW, BFRIW, CINGW, CMRAW, and CDTTW

Should you buy Clever Leaves stock or one of its competitors? Clever Leaves's main competitors and comparable companies include 60 Degrees Pharmaceuticals (SXTPW), Biofrontera (BFRIW), Cingulate (CINGW), Comera Life Sciences (CMRAW), and Conduit Pharmaceuticals (CDTTW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Clever Leaves compare to 60 Degrees Pharmaceuticals?

60 Degrees Pharmaceuticals (NASDAQ:SXTPW) and Clever Leaves (NASDAQ:CLVR) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk, profitability and media sentiment.

60 Degrees Pharmaceuticals has higher earnings, but lower revenue than Clever Leaves.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
60 Degrees Pharmaceuticals$1.11MN/AN/AN/AN/A
Clever Leaves$17.42M0.00-$17.90M-$9.66N/A

6.9% of Clever Leaves shares are owned by institutional investors. 8.2% of Clever Leaves shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, 60 Degrees Pharmaceuticals had 1 more articles in the media than Clever Leaves. MarketBeat recorded 1 mentions for 60 Degrees Pharmaceuticals and 0 mentions for Clever Leaves. 60 Degrees Pharmaceuticals' average media sentiment score of 1.99 beat Clever Leaves' score of 0.00 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
60 Degrees Pharmaceuticals Very Positive
Clever Leaves Neutral

Company Net Margins Return on Equity Return on Assets
60 Degrees PharmaceuticalsN/A N/A N/A
Clever Leaves N/A N/A N/A

Summary

Clever Leaves beats 60 Degrees Pharmaceuticals on 3 of the 5 factors compared between the two stocks.

How does Clever Leaves compare to Biofrontera?

Biofrontera (NASDAQ:BFRIW) and Clever Leaves (NASDAQ:CLVR) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.

6.9% of Clever Leaves shares are held by institutional investors. 8.2% of Clever Leaves shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Biofrontera's average media sentiment score of 0.00 equaled Clever Leaves'average media sentiment score.

Company Overall Sentiment
Biofrontera Neutral
Clever Leaves Neutral

Company Net Margins Return on Equity Return on Assets
BiofronteraN/A N/A N/A
Clever Leaves N/A N/A N/A

Biofrontera has higher revenue and earnings than Clever Leaves.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biofrontera$46.18MN/AN/AN/AN/A
Clever Leaves$17.42M0.00-$17.90M-$9.66N/A

Summary

Clever Leaves beats Biofrontera on 2 of the 3 factors compared between the two stocks.

How does Clever Leaves compare to Cingulate?

Clever Leaves (NASDAQ:CLVR) and Cingulate (NASDAQ:CINGW) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

Company Net Margins Return on Equity Return on Assets
Clever LeavesN/A N/A N/A
Cingulate N/A N/A N/A

6.9% of Clever Leaves shares are held by institutional investors. 8.2% of Clever Leaves shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Cingulate has lower revenue, but higher earnings than Clever Leaves.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Clever Leaves$17.42M0.00-$17.90M-$9.66N/A
CingulateN/AN/AN/AN/AN/A

In the previous week, Clever Leaves' average media sentiment score of 0.00 equaled Cingulate'saverage media sentiment score.

Company Overall Sentiment
Clever Leaves Neutral
Cingulate Neutral

Summary

Clever Leaves beats Cingulate on 3 of the 3 factors compared between the two stocks.

How does Clever Leaves compare to Comera Life Sciences?

Comera Life Sciences (NASDAQ:CMRAW) and Clever Leaves (NASDAQ:CLVR) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, media sentiment, analyst recommendations, earnings and risk.

In the previous week, Comera Life Sciences' average media sentiment score of 0.00 equaled Clever Leaves'average media sentiment score.

Company Overall Sentiment
Comera Life Sciences Neutral
Clever Leaves Neutral

Comera Life Sciences has higher earnings, but lower revenue than Clever Leaves.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Comera Life Sciences$1.00MN/AN/AN/AN/A
Clever Leaves$17.42M0.00-$17.90M-$9.66N/A

Company Net Margins Return on Equity Return on Assets
Comera Life SciencesN/A N/A N/A
Clever Leaves N/A N/A N/A

6.9% of Clever Leaves shares are held by institutional investors. 8.2% of Clever Leaves shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Clever Leaves beats Comera Life Sciences on 3 of the 3 factors compared between the two stocks.

How does Clever Leaves compare to Conduit Pharmaceuticals?

Clever Leaves (NASDAQ:CLVR) and Conduit Pharmaceuticals (NASDAQ:CDTTW) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, media sentiment, profitability, valuation, dividends and earnings.

In the previous week, Clever Leaves' average media sentiment score of 0.00 equaled Conduit Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Clever Leaves Neutral
Conduit Pharmaceuticals Neutral

Conduit Pharmaceuticals has lower revenue, but higher earnings than Clever Leaves.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Clever Leaves$17.42M0.00-$17.90M-$9.66N/A
Conduit PharmaceuticalsN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
Clever LeavesN/A N/A N/A
Conduit Pharmaceuticals N/A N/A N/A

6.9% of Clever Leaves shares are owned by institutional investors. 8.2% of Clever Leaves shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Clever Leaves beats Conduit Pharmaceuticals on 3 of the 3 factors compared between the two stocks.

Get Clever Leaves News Delivered to You Automatically

Sign up to receive the latest news and ratings for CLVR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CLVR vs. The Competition

Export
MetricClever LeavesPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market CapN/A$12.24B$7.26B$12.73B
Dividend YieldN/A2.59%2.53%8.86%
P/E Ratio0.00787.26273.3025.25
Price / Sales0.00754.39617.9597.64
Price / CashN/A94.8077.8252.26
Price / Book0.0012.3213.036.14
Net Income-$17.90M$2.82B$3.47B$349.01M
7 Day PerformanceN/A2.56%0.52%-0.31%
1 Month PerformanceN/A6.92%5.63%0.64%
1 Year PerformanceN/A9.42%25.32%14.83%

Clever Leaves Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CLVR
Clever Leaves
N/A$0.00
flat		N/AN/A$0.00$17.42MN/A560
SXTPW
60 Degrees Pharmaceuticals
N/A$0.04
+55.7%		N/A-62.0%$0.00$1.11MN/A2
BFRIW
Biofrontera
N/A$0.03
flat		N/A-83.7%$0.00$46.18MN/A70
CINGW
Cingulate
N/A$0.01
-38.7%		N/A-84.3%$0.00N/AN/A20
CMRAW
Comera Life Sciences
N/AN/AN/AN/A$0.00$1.00MN/A2

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CLVR) was last updated on 9/4/2026 by MarketBeat.com Staff.
From Our Partners
The 2026 beginners Guide to Gold IRAs
Gold trades near record highs while silver just topped $81 an ounce for the first time ever. Thousands of A...
Goldco Direct, LLC | Sponsoredtc pixel
Are you leaving Social Security money on the table?
Most retirement plans still have gaps in them... The quiet ones that don't show up until it's too late to fix....
Money Pickle | Sponsoredtc pixel
How Long Does $2.5M Last in Retirement?
Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...
SmartAsset | Sponsoredtc pixel
A Simple Guide to Options Trading While It's Still Free
A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...
True Market Insiders | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Rickards Predicts: Trump to buy tiny $2 stock?
Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...
Paradigm Press | Sponsoredtc pixel
Major Buy Alert Issued for September 30th
Keith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...
TradeSmith | Sponsoredtc pixel
Before Anthropic becomes impossible to ignore...
Riot Platforms just struck a 20-year, 191-megawatt data-center agreement tied to Anthropic, reportedly worth 9...
The Oxford Club | Sponsoredtc pixel